Design Prospective cohort study. Objective We assessed the diagnostic yield of trio-based WES (fetus and both parents) in pregnancies with sonographic findings and prior negative results from quantitative fluorescent PCR (QF-PCR), conducted in parallel with CMA. Settings Prenatal genetic testing was conducted within the public health system of the Balearic Islands, Spain. Testing was performed at the Molecular Diagnostics and Clinical Genetics Unit at Hospital Universitari Son Espases, with samples from multiple regional hospitals. Population or samples Trio samples from 249 pregnancies with ultrasound fetal structural anomalies. Methods Parallel trio-based WES and CMA were performed. Molecular findings were classified, and diagnostic yield was analyzed across anomaly categories. Clinical management outcomes were also recorded. Main Outcome
Measures Diagnostic yield of trio-based WES and its influence on clinical management. Results A molecular diagnosis was established in 26.9% (67/249) of cases. Variant distribution included 58.2% de novo autosomal-dominant, 29.9% autosomal-recessive, 9.0% inherited dominant, and 3.0% X-linked. Diagnostic yield varied by anomaly category, ranging from 37.5% in growth disorders to 6.3% in gastrointestinal anomalies. The median turnaround time was 12 days. Pregnancy termination occurred in 54.7% of diagnosed cases compared to 18.1% among those without a diagnosis. Conclusions Prenatal parallel trio-based WES and CMA following negative QF-PCR results could represent an appropriate and actionable strategy in the current prenatal diagnostic landscape. This approach provides a significantly improved diagnostic yield and faster turnaround time, thereby delivering meaningful support to families facing complex prenatal decision-making. Funding The authors did not receive support from any organization. Keywords: Microarray Analysis; Exome Sequencing; Ultrasonography, Prenatal; Clinical Decision‑Making; Prenatal Diagnosis.
Congenital heart defects (CHDs) occur in 50–75% of patients with 22q11.2 deletion syndrome (22q11.2DS), ranging from mild to severe manifestations. The genetic and environmental factors contributing to variable CHD phenotypes in 22q11.2DS are largely unknown. In this study, we used a mouse model of 22q11.2DS, termed Df1/+, to evaluate the effect of maternal vitamin A (VitA) dietary imbalance (supplementation or deficiency) on the incidence of aortic arch defects (AADs), which is a common type of CHD observed in both 22q11.2DS patients and Df1/+ mouse embryos. While most groups showed a previously observed 30% AAD incidence, two groups exhibited significantly higher rates: (1) Df1/+ embryos from WT mothers on a VitA-Supl diet (51% AADs) and (2) Df1/+ embryos from Df1/+ mothers on a VitA-Def diet (45% AADs). Thus, a low or high maternal VitA diet can increase the frequency of AADs in embryos depending on the maternal genotype. Transcriptomic analysis of the hearts of these high-risk embryos at embryonic day (E)18.5 revealed downregulation of key genes (Hdac3, Ptgds, Sirt5, Pfkm, and Lclat1) associated with energy metabolism pathways, such as oxidative phosphorylation and glycolysis, suggesting impaired cardiac recovery mechanisms. In conclusion, our findings demonstrate that altered VitA exposure can exacerbate AAD incidence in a maternal-genotype-dependent manner, highlighting the complex interplay between embryonic and maternal genetic background and environmental factors in CHDs associated with 22q11.2DS.